MoneyWorks4Me

The Revenue for the quarter ended  September 2022 of Rs. 13794.80 millions grew by 12.88 % from Rs. 12220.60 millions.A good growth in profit of 38.05% reported to Rs. 2655.20  millions over Rs. 1923.30 millions of corresponding previous quarter.The company reported a good operating profit of 3768.30 millions compared to 2779.00 millions of corresponding previous quarter.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202209 202109 % Var 202209 202109 % Var 202203 202103 % Var
Sales 13794.80 12220.60 12.88 26838.50 24398.90 10.00 49192.70 43100.20 14.14
Other Income 335.30 182.10 84.13 598.90 374.20 60.05 772.10 809.00 -4.56
PBIDT 3768.30 2779.00 35.60 6735.90 5622.60 19.80 11649.30 10023.60 16.22
Interest 39.70 45.10 -11.97 81.90 95.50 -14.24 191.00 182.80 4.49
PBDT 3728.60 2733.90 36.38 6654.00 5527.10 20.39 11458.30 9840.80 16.44
Depreciation 174.70 162.00 7.84 348.20 319.30 9.05 661.00 581.30 13.71
PBT 3553.90 2571.90 38.18 6305.80 5207.80 21.08 10797.30 9259.50 16.61
TAX 898.70 648.60 38.56 1594.20 1326.90 20.14 2810.30 2352.60 19.46
Deferred Tax -18.30 -41.60 -56.01 -30.50 -69.40 -56.05 41.80 -37.90 -210.29
PAT 2655.20 1923.30 38.05 4711.60 3880.90 21.40 7987.00 6906.90 15.64
Equity 212.50 212.50 0.00 212.50 212.50 0.00 212.50 212.50 0.00
PBIDTM(%) 27.32 22.74 20.13 25.10 23.04 8.91 23.68 23.26 1.82
Peers
Company Name CMP
Sun Pharma. Inds. 1853.50
Dr. Reddys Labs. 1202.80
Cipla 1397.20
Lupin 2090.00
Zydus Lifesciences 1202.00
View more..